Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252220 · ClinicalTrials.gov registry record · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
A Phase 1 study of Obesity, sponsored by NeuroBo Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 139
- Enrollment target
- 1
- Study location
NCT06252220: Recruiting Phase 1 study of Obesity, sponsored by NeuroBo Pharmaceuticals.
NCT06252220 is a Phase 1 study of Obesity that is actively recruiting participants, run by NeuroBo Pharmaceuticals. The registered enrollment target is 139 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252220, a Phase 1 study of Obesity, is actively recruiting participants, sponsored by NeuroBo Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 139 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
Primary Outcome
AEs, SAEs, TEAEs and AEs leading to treatment discontinuation.
Conditions Studied
Interventions
- DRUG DA-1726
- DRUG Placebo to DA-1726
Study Locations (1)
Florida
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-11-09 |
| Phase | Phase 1 |
What NCT06252220 shows while recruiting
NCT06252220 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which DA-1726 is the first listed.
NCT06252220 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06252220 about?
NCT06252220 is a clinical study titled "First in Human Study in Subjects With Obesity, But Otherwise Healthy". This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
What is the current status of trial NCT06252220?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2024-03-25. Estimated completion is 2026-11-09.
What conditions does trial NCT06252220 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06252220?
The interventions under investigation include: DA-1726 (DRUG), Placebo to DA-1726 (DRUG).
Who is sponsoring clinical trial NCT06252220?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252220 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06252220's enrollment target sits among peer trials
139 405th of 1053 higher than 648 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI